Australia’s National Centre for Neuroimmunology and Emerging Diseases (NCNED) announced at its recent International Conference on Research, Innovation and Discovery, the establishment of the Consortium Health International for ME (CHIME).
This Consortium consists of multi-site, multi-national collaboration with NCNED across Australia, United States of America, United Kingdom, New Zealand, Poland, Germany and Japan to undertake research investigations into diagnosis, treatment, epidemiology/demographics and health services delivery for CFS/ME.
It is intended the CHIME Consortium will provide an international reference point for CFS/ME research worldwide. CHIME aims to create transformational change in how CFS/ME is diagnosed and treated by establishing a clear nexus between pathomechanism discovery, development of a screening/diagnostic test, and drug development and/or repurposing which will be applied in revised clinical guidelines internationally.
Enhanced epidemiological surveillance and demographic understanding of the illness will be expanded in the context of health services planning and utilisation in CFS/ME. This approach will enable a more standardised approach to these elements of CFS/ME research and treatment world-wide.